Low Expectations May Cause Patients to Stop Taking Infliximab Biosimilar, Study Suggests
A study of patients with ankylosing spondylitis, rheumatoid arthritis, and psoriatic arthritis who switched from Remicade (infliximab) therapy to a biosimilar, sold as Remsima or Inflectra (CT-P13), showed that 24% of patients stopped taking the therapy within six months for reasons that appear unrelated to the therapy’s health benefits. The…